Story · Medicine & Biotech

David OMalley: Does Olaparib Plus Tremelimumab Offer New Hope for PARP-Resistant Ovarian Cancer?

1 outlet · first reported by OncoDaily 1d ago

Coverage, in order

  1. 1d ago
    OncoDaily obscure
    David OMalley: Does Olaparib Plus Tremelimumab Offer New Hope for PARP-Resistant Ovarian Cancer?

    David OMalley, Director of Translational and Clinical Research Partnerships; Leader, Clinical Trial Innovation at Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, shared on LinkedIn: “Proud

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.